Literature DB >> 9733266

Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis.

A R Hartman1, S F Williams, J J Dillon.   

Abstract

Randomized, prospective studies comparing BUCY to TBI conditioning regimens for allogeneic bone marrow transplantation have yielded conflicting results. We investigated the overall survival, the disease-free survival and the toxicities of BUCY vs TBI-based regimens by conducting a meta-analysis of all published, randomized, prospective trials comparing these regimens. Five studies were analyzed. We evaluated six endpoints: survival, disease-free survival, veno-occlusive disease (VOD) of the liver, acute GVHD, chronic GVHD, and interstitial pneumonitis. We combined individual study results using a random effects model. Survival and disease-free survival were better with TBI-based regimens than with BUCY, but these differences were not statistically significant (survival odds ratio 1.4, 95% confidence interval 0.9-2.2, P = 0.09; disease-free survival odds ratio 1.2, 95% confidence interval 0.7-2.1, P = 0.44). A power analysis indicated that BUCY was unlikely to have a clinically relevant survival or disease-free survival advantage. The power analysis could not exclude the possibility of such an advantage for TBI-based regimens. A significantly greater incidence of VOD occurred with BUCY (odds ratio 2.5, 95% confidence interval 1.2-5.2, P = 0.02). For the other side-effects, there were no significant differences. We concluded that TBI-based regimens cause less VOD than BUCY and are at least as good for survival and disease-free survival.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733266     DOI: 10.1038/sj.bmt.1701334

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  32 in total

1.  Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation.

Authors:  Jeffrey Y C Wong; Stephen Forman; George Somlo; Joseph Rosenthal; An Liu; Timothy Schultheiss; Eric Radany; Joycelynne Palmer; Anthony Stein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-15       Impact factor: 7.038

2.  The war on cancer: a report from the front lines.

Authors:  Gavin Melmed
Journal:  Proc (Bayl Univ Med Cent)       Date:  2006-10

3.  Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia.

Authors:  Borje S Andersson; Marcos de Lima; Peter F Thall; Timothy Madden; James A Russell; Richard E Champlin
Journal:  Curr Opin Oncol       Date:  2009-06       Impact factor: 3.645

4.  Cardiopulmonary exercise testing prior to myeloablative allo-SCT: a feasibility study.

Authors:  C R Kelsey; J M Scott; A Lane; E Schwitzer; M J West; S Thomas; J E Herndon; M G Michalski; M E Horwitz; T Hennig; L W Jones
Journal:  Bone Marrow Transplant       Date:  2014-07-28       Impact factor: 5.483

Review 5.  Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.

Authors:  Benigno C Valdez; Borje S Andersson
Journal:  Environ Mol Mutagen       Date:  2010-07       Impact factor: 3.216

6.  Antibody Conditioning Enables MHC-Mismatched Hematopoietic Stem Cell Transplants and Organ Graft Tolerance.

Authors:  Benson M George; Kevin S Kao; Hye-Sook Kwon; Brenda J Velasco; Jessica Poyser; Angela Chen; Alan C Le; Akanksha Chhabra; Cassandra E Burnett; Devon Cajuste; Malachia Hoover; Kyle M Loh; Judith A Shizuru; Irving L Weissman
Journal:  Cell Stem Cell       Date:  2019-06-13       Impact factor: 24.633

Review 7.  Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma.

Authors:  Vijaya Raj Bhatt
Journal:  Curr Hematol Malig Rep       Date:  2016-06       Impact factor: 3.952

Review 8.  Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions.

Authors:  Abraham S Kanate; Marcelo C Pasquini; Parameswaran N Hari; Mehdi Hamadani
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

9.  Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS.

Authors:  J De La Serna; J Sanz; A Bermúdez; M Cabrero; D Serrano; C Vallejo; V Gómez; J M Moraleda; S G Perez; M D Caballero; E Conde; J J Lahuerta; G Sanz
Journal:  Bone Marrow Transplant       Date:  2016-03-07       Impact factor: 5.483

10.  A Review of Radiation-Induced Coagulopathy and New Findings to Support Potential Prevention Strategies and Treatments.

Authors:  Ann R Kennedy; Amit Maity; Jenine K Sanzari
Journal:  Radiat Res       Date:  2016-07-26       Impact factor: 2.841

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.